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Non-absorbable disaccharides (NADs) have been used to treat hepatic 
encephalopathy (HE) since 1966.  However, a Cochrane review, published in 2004, 
found insufficient evidence to recommend their use in this context.  This updated 
systematic review evaluates the effects of the NADs, lactulose and lactitol, for the 
treatment and prevention of HE in patients with cirrhosis.  Thirty-eight randomized 
controlled trials (RCTs), involving 1828 patients, were identified via electronic and 
manual searches; 31 RCTs looked at the treatment of HE while seven looked at its 
primary/secondary prevention.  Random-effects meta-analyses showed that, 
compared to placebo/no intervention, NADs had a beneficial effect on HE (relative 
risk [RR], 0.63; 95% confidence interval [CI], 0.53-0.74; Number Needed to Treat 
[NNT] = 4) and serious liver-related adverse events such as: liver failure, variceal 
bleeding, serious infections, spontaneous bacterial peritonitis and hepatorenal 
syndrome (RR, 0.42; 95% CI, 0.26-0.69; NNT = 50).  Treatment was also associated 
with a reduction in mortality in patients with overt HE (RR, 0.36; 95% CI, 0.14-0.94; 
NNT = 20), although not in patients with minimal HE.  Meta-analyses of the 
prevention RCTs showed that NADs prevented the development of HE (RR, 0.47; 
95% CI, 0.33-0.68; NNT = 6), the risk of developing serious liver-related adverse 
events (RR, 0.48; 95% CI, 0.33-0.70; NNT = 6), and reduced mortality (RR, 0.63; 95% 
CI, 0.40-0.98; NNT = 20).  Use of NADs was associated with non-serious 
gastrointestinal adverse events.  There were no differences in the efficacy or safety 
of lactulose and lactitol. Conclusions: NADs have beneficial effects in the 
treatment and prevention of HE; their use, in this context, confers additional 
benefits including a reduction in serious liver-related morbidities and all-cause 
mortality.  
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In 1966, Johannes Bircher published the first report of the use of lactulose to treat hepatic 
encephalopathy (HE).1, 2  This non-absorbable disaccharide (NAD) was adopted as the 
treatment of choice for this condition replacing dietary manipulation and the non-
absorbable antibiotic neomycin.  The second generation NAD, lactitol, was introduced 
into clinical practice in the 1980’s.3-6   
The NADs are classified as osmotic laxatives, but have also been classified as prebiotics, 
a generic term referring to agents that induce the growth or activity of commensal micro-
organisms.  Although the pathogenesis of HE is incompletely understood there is a 
general agreement that the gut-derived neurotoxin ammonia plays a key role.7  NADs 
reduce the intestinal production/absorption of ammonia via several potential mechanisms, 
viz: (i) catharsis: the colonic metabolism of the NADs results in an increase in intraluminal 
gas formation and intraluminal osmolality and a reduction in intraluminal pH and transit 
time; (ii) bacterial uptake of ammonia: the volatile fatty acids released during the colonic 
metabolism of NADs are utilized as a preferred substrate by the colonic bacteria with 
ammonia as the nitrogen source for protein synthesis.  The increase in bacterial numbers 
additionally ‘bulks’ the stool and contributes to the cathartic effect;8 (iii) intestinal 
ammonia production: NADs inhibit glutaminase activity and interfere with the intestinal 
uptake of glutamine and its subsequent metabolism to ammonia;9 (iv)  gut microbiome: 
cirrhosis is associated with dysbiosis and changes in the colonic microbiome;10 additional 
changes in the microbiome may be observed in patients with HE.11  NADs can 
beneficially affect microbiota composition.11   
The efficacy and safety of NADs for the treatment of HE has been assessed in a number 
of randomized controlled trials (RCTs) although many of the earlier studies can be 
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criticized, if judged by today’s much more rigorous standards.  A Cochrane review, 
published in 2004,12 evaluated NADs versus placebo or no intervention and found a 
beneficial effect on HE, but no effect on mortality.  However, there were a number of 
methodological issues including the reporting of bias domains and the lack of statistical 
power, which weakened the strength of the conclusions.  The publication of this review 
did, however, resulted in the undertaking and publication of a large number of additional 
RCTs of relevance. 
In 2014, the European and American Associations for the Study of the Liver 
(EASL/AASLD) published a joint practice guideline in which they recommended lactulose 
as the treatment of choice for overt HE and for its secondary prevention after an index 
event.13  They did not recommend routine treatment for minimal HE, but stated that 
exceptions could be made, on a case-by-case basis, if driving skills, work performance, 
quality of life or cognitive function were impaired.  They did not recommend primary 
prophylaxis for the prevention of HE except in patients ‘known to be at high risk’ but not 
otherwise defined.  The guideline mentioned that lactitol is preferred in some centers but 
did not comment on the relative efficacy and safety of the two agents.  The authors of the 
EASL/AASLD practice guideline based their recommendations on clinical experience and 
on a formal review and analysis of recently published literature.  
The advent of the new RCTs and the contrary views expressed in the 2004 Cochrane 
review and the 2014 EASL/AASLD practice guideline prompted this update of the use of 
NADs in patients with cirrhosis.  The updated review includes a larger number of RCTs 
and is based on the current methodology for systematic reviews. Unlike the 2004 
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Cochrane review, the primary outcomes now include serious adverse events as well as 
hepatic encephalopathy and mortality. 
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Materials and Methods 
This paper is an abbreviated version of an updated and revised Cochrane systematic 
review.12 It addresses the clinical utility and safety of NADs for the treatment and 
prevention of hepatic encephalopathy in patients with cirrhosis in comparison with 
placebo/no intervention.   
Data Sources and Searches. A language-unrestricted search was made of the 
Cochrane Hepato-Biliary Group Controlled Trials Register, the Cochrane Library, 
MEDLINE, EMBASE, and Science Citation Index.  The generic search strategy was 
devised by the Trial Search Coordinator at the Cochrane Hepato-Biliary Editorial Team; it 
was then adjusted for each different search platform (Supplementary Table 1).  The last 
search update was undertaken in December 2015.  
In addition, the bibliographies of relevant papers, specialist journals, conference 
proceedings, and trial registries were searched and contact made with the principal 
authors of published trials, and relevant pharmaceutical companies to obtain missing or 
additional trial data.  
Study Selection. Two review authors (LG and MYM) independently scrutinized the 
electronic searches, performed the additional manual searches, and listed all potentially 
eligible RCTs.  All three authors reviewed this material and participated in the final 
selection of RCTs, which was agreed by consensus.  RCTs were included regardless of 
their publication status, language, blinding, or design.  Only the first period of cross-over 
trials, in which patients were randomized to lactulose/lactitol or placebo/no intervention, 
was included.14  
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Translations of non-English papers were obtained from commercial translation services 
or medical personnel fluent in the relevant language.  
Data Extraction. Two review authors independently retrieved preselected data from the 
selected RCT reports including:  
i) Study-specific information: date of publication; inclusion period; investigation sites; 
study design; 
ii) Patient-specific information: age, gender distribution, aetiology of cirrhosis, type of 
hepatic encephalopathy; previous history of hepatic encephalopathy;  
iii) Treatment –specific information: comparative regimens; numbers of patients assigned 
to each intervention arm; dose, duration and pattern of treatment; mode of 
administration; use of adjuvant anti-encephalopathy treatment; 
iv) Information on evaluation/outcome variables, viz: mental state, which was usually 
assessed using the West Haven criteria;15 asterixis; Number Connection Test-A 
(NCT-A) time;16 other psychometric test results; venous/arterial blood ammonia 
concentrations; electroencephalogram (EEG) mean dominant frequency (mdf).  These 
variables were used in combination, in several studies, often after transformation 
using a semi-quantitative scoring system, to provide a composite ‘overall assessment 
of hepatic encephalopathy’.  The scoring schema most frequently used was the 
Portal-Systemic Encephalopathy (PSE) sum/index,15 which is calculated utilizing five 
variables, viz: mental status, the presence and severity of asterixis; the NCT-A time, 
blood ammonia concentration; and the EEG mdf.  Each variable is assigned a score 
of 0 (no abnormality) to 4 (severe abnormality) and the PSE index calculated as the 
Page 8 of 61
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
9 
ratio of the points scored and the maximum possible score of 28.  The assessment of 
HE outcome was based on the authors’ evaluation.17 Data on quality of life were 
extracted where available.   
Independent data collections were compared and contrary opinions resolved through 
discussion.  
Outcome Measures. All outcomes were evaluated at the maximum duration of follow 
up.18  The primary outcome measures were hepatic encephalopathy viz. the number of 
patients without clinically relevant improvement; all-cause mortality, and serious adverse 
events, which in this population were inevitable related to the underlying liver disease, for 
example: liver failure, variceal hemorrhage, serious infections, including spontaneous 
bacterial peritonitis, and hepatorenal syndrome.  The secondary outcomes measures 
were quality of life and non-serious adverse events such as abdominal pain, diarrhea, 
vomiting, nausea, flatulence, anorexia and headache. 
Assessment of Bias Risk. The assessment of bias control was based on six domains 
viz: selection bias, performance and detection bias, attrition bias, reporting bias, for-profit 
bias and other bias, (Supplementary Table 2).18  The risk of bias for the individual 
domains was classified as low, unclear (insufficient information provided), and high.  The 
six domains were combined into an overall score which was classified as low if all six 
individual domains were classified as low risk of bias and high if one or more of the 
domains was classified as unclear/high risk of bias.  
Data synthesis and analysis. Outcomes were analyzed using random-effects meta-
analyses18 and the effect measures reported as relative risk (RR) or mean differences 
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(MD) with 95% confidence intervals (CIs) and I2 values as a marker of heterogeneity.  I2 
values of zero to 40% were classified as unimportant; 40 to 60% as moderate; 60 to 80% 
as substantial, and >80% as considerable.  For statistically significant primary outcomes, 
the numbers needed to treat (NNT) was calculated using 1/risk difference based on the 
best available evidence defined as RCTs with a low risk of bias in the overall assessment 
if available.  For meta-analyses which included at least ten trials, publication bias and 
other small study effects were assessed using regression analyses.19   
Separate analyses were undertaken of RCTs evaluating the treatment of HE and the 
prevention of HE.  In addition, subgroup and sensitivity analyses were undertaken to 
analyse RCTs (i) with a low risk of bias; and those evaluating: (ii) minimal or overt HE; (iii) 
acute (episodic) or chronic (recurrent and persistent) HE and (iv) primary or secondary 
prevention; 
The analyses were performed using RevMan version 5 (Nordic Cochrane Centre, 
Copenhagen Denmark) and STATA version 14 (Stata Corp, Texas USA).  The results are 
reported based on the preferred reporting items for systematic reviews and meta-
analyses (PRISMA) statement.20  
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Results  
Search results. The electronic searches generated 1378 potentially eligible records 
while the manual searches identified an additional 10 records (Fig. 1).  After removal of 
duplicate and irrelevant references, a total of 82 records remained and were retrieved for 
further assessment.  Of these, 38 RCTs4-6, 21-55 fulfilled the inclusion criteria (Table 1).  
Qualitative data were available from all 38 trials, involving 1828 patients, while 
quantitative data were available from 34 trials, involving 1764 patients.  
Included RCTs. The utility of NADs for the treatment of HE was evaluated in 31 RCTs.  
Sixteen of these RCTs evaluated treatment effects in patients with overt HE classified as 
either acute (seven RCTs) or chronic (nine RCTs).  In the latest recommended 
nomenclature,13 the diagnosis ‘acute’ HE corresponds to the term ‘episodic’ while 
‘chronic’ HE corresponds to the terms recurrent or persistent (Supplementary Table 3).  
The remaining 15 RCTs evaluated treatment effects in patients with minimal HE. 
The prevention of HE was evaluated in seven RCTs.  Three RCTs evaluated primary 
prevention in patients with no previous history of HE or secondary prevention in people 
with no immediately obvious risk factors for HE.  The remaining four RCTs included 
patients with an increased risk of HE due to gastrointestinal bleeding, recent insertion of a 
transjugular intrahepatic portosystemic shunt, or portosystemic shunt surgery.  Six of the 
prevention trials compared NADs versus placebo/no intervention while the remaining 
prevention trial compared lactulose versus lactitol.  
In total, 29 trials compared NADs versus placebo/no intervention (Table 1) and nine 
compared lactulose versus lactitol.  The duration of follow-up in the individual RCTs 
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varied in relation to the type of HE and the study design.  Thus, the duration of follow-up 
was four to seven days in RCTs evaluating acute HE, 10 to 360 days in RCTs evaluating 
chronic HE; 14 to 180 days in RCTs evaluating minimal HE and 5 to 360 days in RCTs 
evaluating prevention depending on whether this was primary or secondary.  
A variety of methods were used, in the included RCTs to assess patients’ 
neuropsychiatric status and to classify outcomes (Supplementary Table 3).  Eight used 
the PSE Sum/Index.5, 6, 29, 36, 40, 41, 48, 49 Two used the PSE Sum/Index modified by 
omission of the EEG27 and replacement of the NCT-A with the Digit Symbol test.39  Ten of 
the remaining RCTs used West Haven Criteria to assess mental status.21, 31, 32, 35, 37, 43-45, 
51, 55  Three RCTs used the Conn Score, which is similar to the West Haven Criteria.4, 28, 
50  Thirty-two RCTs employed  NCT-A.4-6, 21, 24, 26-41, 43, 45, 46, 48-55  Twenty-five RCTs 
measured blood ammonia in plasma, venous, or arterial blood.5, 6, 21-23, 25-29, 31, 35, 36, 38-41, 44, 
46-49, 52, 54, 55 while 22 assessed the electroencephalogram mean cycle frequency.4-6, 21-23, 
25, 26, 28-30, 32, 36, 38-42, 48, 49, 52, 54  
Bias Assessment.  The risk of selection bias was low in 23 RCTs (Supplementary Table 
4).  Fourteen RCTs were conducted double blind and so had a low risk of performance 
and detection bias while six were conducted with a blinded outcome assessment and had 
a low risk of detection bias.  The risk of attrition bias was low in 22 RCTs while the risk of 
outcome bias was low in 32 trials.  Nineteen trials were free of for-profit funding bias.  No 
other biases were identified.  In the overall bias assessment, eight RCTs were classed as 
of low risk of bias in the analysis of mortality.  None was classified as of low risk in the 
assessment of the remaining outcomes. 
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TREATMENT TRIALS COMPARING NADS VERSUS PLACEBO/NO INTERVENTION  
Primary outcomes. Treatment with NADs was associated with a beneficial effect on HE 
compared to placebo/no intervention (RR, 0.63; 95% CI: 0.53-0.74; NNT = 4; 747 
patients; 16 RCTs; I2 = 25%) (Fig. 2).  This effect was seen in the five RCTs evaluating 
overt HE (RR, 0.62; 95% CI: 0.39-0.99; 140 patients; NNT = 5) and in the 11 RCTs 
evaluating minimal HE (RR, 0.63; 95% CI: 0.52-0.76; 607 patients; NNT = 4).  Within the 
overt HE group treatment was equally effective in those with acute and chronic HE (data 
not shown). 
Treatment with NADs had a beneficial effect on mortality (RR, 0.49; 95% CI: 0.23-1.05; 
NNT = 100; 819 patients; 18 RCTs; I2 = 0%) (Fig. 3).  This effect was seen in the six 
RCTs evaluating overt HE (RR, 0.36; 95% CI: 0.14-0.94; 172 patients; NNT = 20), but not 
in the 12 RCTs evaluating minimal HE (RR, 0.82; 95% CI: 0.24-2.86; 647 patients).  
Within the overt HE group, treatment had a beneficial effect on mortality in patients with 
acute HE. The results in the chronic HE group were not separately estimable (data not 
shown).  Three of the included RCTs had a low risk of bias. All three included patients 
with minimal HE.  Analysis of the three trials found no effect of NADs on mortality (RR 
0.56, 95% CI 0.12 to 2.86).  
The serious adverse events reported were primarily liver-related and included liver failure, 
variceal bleeding, severe infections, primarily respiratory and urinary tract, spontaneous 
bacterial peritonitis, and hepatorenal syndrome.  Treatment with NADs was associated 
with a beneficial effect on serious adverse events (RR, 0.42; 95% CI: 0.26-0.69; NNT = 
50; I2 = 0%; 819 patients; 18 RCTs).  The effect was seen both in patients with overt HE 
(RR, 0.40; 95% CI, 0.16-0.1.02; NNT = 25; 140 patients; six RCTs) and in patients with 
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minimal HE (RR, 0.43; 95% CI, 0.24-0.78; NNT = 50; 607 patients; 12 RCTs).  Within the 
overt HE group, treatment reduced the risk of serious adverse events in patients with 
acute HE, but the result in the chronic HE group was not separately estimable (data not 
shown).  There were no differences in serious adverse events between the intervention 
and control groups when they were analyzed individually rather than collectively 
(Supplemental table 5). 
None of the analyses of the primary outcomes showed evidence of publication bias or 
other small study effects in regression analyses.  
Secondary outcomes. Six RCTs included quality of life data; three RCTs involving 160 
patients with minimal HE utilized the Sickness Impact Profile allowing the results to be 
analyzed.  Two of these RCTs found a beneficial effect of lactulose reflected in the 
change in the overall score from baseline to the end of treatment (MD, 7.18; 95% CI, 
5.28-9.07; I2 = 53%), while the third trial found no difference between end of treatment 
values (MD 0.90; CI -4.13-5.93).  
Treatment with NADs was associated with an increased risk of non-serious adverse 
events, including diarrhea, bloating, flatulence and nausea.  However, the risk of these 
events did not differ between patients allocated to NADs or placebo/no intervention (RR, 
2.12; 95% CI, 0.62-7.28; 201 patients, five RCTs, I2 = 62%).  
NAD VERSUS PLACEBO/NO INTERVENTION: PREVENTION RCTS  
Primary outcomes. NADs had a beneficial effect on the prevention of HE when all six 
trials were included (RR, 0.47; 95% CI, 0.33-0.68; NNT = 6; 668 patients, I2 = 30%) and 
when including the five RCTs with a low risk of bias (RR, 0.50; 95% CI, 0.35-0.71, NNT = 
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5; 538 patients; I2 = 27%).  NADs had utility for both the primary (RR, 0.48; 95% CI: 0.23-
0.98; NNT = 7; 370 patients; four RCTs) and secondary prevention of HE (RR, 0.44; 95% 
CI: 0.31-0.64; NNT = 4; 298 patients; two RCTs).  
NADs had a beneficial effect on mortality compared to placebo/no intervention when all 
six RCTs were included (RR, 0.47; 95% CI: 0.33-0.68; NNT = 20; 668 patients; I2 = 0%) 
or when including the five RCTs with a low bias risk (RR 0.64, 95% CI 0.41 to 0.99; NNT 
= 33) (Fig. 4).  However, the effect was not seen in subgroup analyses of the four primary 
prevention RCTs (RR, 0.56; 95% CI, 0.27-1.17) or the two secondary prevention RCTs 
(RR, 0.67; 95% CI, 0.39-1.16).   
Treatment with NADs reduced the risk of developing serious adverse events in the 
analysis of the six prevention RCTs (RR 0.63, 95% CI 0.40 to 0.98; NNT = 6; I2 = 0%) 
and when analyzing primary (RR, 0.50; 95% CI: 0.24-1.03; NNT = 8) or secondary 
prevention (RR, 0.44; 95% CI: 0.31-0.64; NNT = 4).  There were no differences in serious 
adverse events between the intervention and control groups when the events were 
analyzed individually rather than collectively (Supplemental table 5). 
Secondary outcomes. None of the prevention RCTs reported data on quality of life.  
Use of NADs in prevention trials increased the risk of non-serious adverse events such 
as bloating, diarrhea, and nausea (RR, 2.78; 95% CI, 1.50-5.13; 548 patients; four 
RCTs).   
LACTULOSE VERSUS LACTITOL: TREATMENT AND PREVENTION.  
There were no difference between the effects of lactulose versus lactitol on HE (RR, 1.00; 
95% CI: 0.84-1.19; 194 patients; seven RCTs), serious adverse events (RR, 1.56; 95% 
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CI, 0.84-2.88; 245 patients; nine RCTs), mortality (RR, 1.30; 95% CI: 0.59-2.85; 225 
patients; eight RCTs), or in the occurrence of non-serious gastrointestinal adverse events 
(RR, 1.55; 95% CI, 0.88-2.74; 169 patients; six RCTs).  
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Discussion  
This updated Cochrane review, found evidence that NADs have  effects which are 
beneficial in the management of patients with minimal and overt HE, but also for the 
primary and secondary prevention of HE.  The use of NADs, in these situations, is also 
associated with a reduction in the risk of developing serious liver-related complications 
such as liver failure, variceal hemorrhage, severe infections, spontaneous bacterial 
peritonitis and hepatorenal syndrome.  In addition, where NADs are used to treat overt 
HE or for HE prevention, there is an associated reduction in mortality.  As expected, use 
of NADs increases the occurrence of non-serious gastrointestinal side-effects such as 
bloating and nausea.  No discernable differences were observed in the efficacy and 
safety of the two available NADs, lactulose and lactitol. 
The reduction in the risk of developing serious liver-related complications and the 
reduction in all-cause mortality associated with use of NADs may relate to an effect on 
the gut microbiome.11, 56 The presence of chronic liver disease is associated with gut 
dysbiosis which has a number of important clinical consequences, including the 
promotion of pathological bacterial translocation,57 which plays an important role in the 
development of infection, and may also trigger development of a profound inflammatory 
state and exacerbate hemodynamic derangements.58  These changes are felt to be key 
to the development of many of the clinical complications of cirrhosis. The beneficial 
effects of NADs on the gut microbiome may interfere with this sequence of events.  
Overall Completeness and Applicability of the Evidence. Information was provided, in 
this review, on the major outcomes of concern in the population under study, namely: 
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morbidity, mortality, adverse events and quality of life.  HE varies widely in its 
manifestation and the RCTs included in this systematic review, represent the entire 
spectrum of the syndrome encountered in people with cirrhosis.  
Episodes of HE often develop in response to a precipitating event such as infection or 
gastrointestinal bleeding.  Identification and treatment of these precipitating factors is key 
to the management of affected individuals, although no obvious precipitating factor is 
identified in 50% of instances.  The RCTs included in this review did not provide detailed 
information on possible precipitating factors, nor on the effects of interventions designed 
to ameliorate them.  Thus, it is not possible to discern whether use of NADs provides 
additional benefit in these situations.  However, in two of the included RCTs, NADs, used 
together with measures to manage upper gastrointestinal hemorrhage, effectively 
prevented the development of HE.  
Patients with HE impose a significant burden on health care systems, and the resource 
utilization associated with their management, in particular the need for hospitalization and 
aftercare, is increasing.59, 60 None of the trials in the present review looked directly at the 
cost-benefits of treatment but it is likely that effective treatment would shorten 
hospitalization while effective prophylaxis would obviate the need for admission.  In this 
regard NADs are cheap and likely to be highly cost-effective. 
Agreements with Other Reviews and Guidelines. The previous version of this review, 
published in 2004,12 included 10 RCTs comparing NADs versus placebo/no intervention; 
six evaluated the treatment of overt HE and four the treatment of minimal HE.  The review 
found that NADs had a beneficial effect on HE compared with placebo/no intervention, 
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but that they had no effect on mortality.  The review did not assess serious adverse 
events.  Based on the high risk of bias and the small number of RCTs, the authors 
concluded that there was insufficient evidence to determine whether NADs have a 
significant beneficial effect on patients with HE.   
The results of this updated review, in contrast, provide consistent evidence that use of 
NADs is associated with beneficial effects on HE, serious liver-related adverse events 
and mortality.  This review was undertaken based on current methodological 
recommendations and employed more extensive manual searches in order to identify 
RCTs, which may be missed in the electronic searches.  In total 38 RCTs comparing 
NADs versus placebo/no intervention were included; of these 16 evaluated the treatment 
of overt HE; 15 the treatment of minimal HE and seven the prevention of HE.  Serious 
adverse events were included as a primary outcome measure.      
The recommendations of the joint EASL/AASLD Practice Guidelines on HE in chronic 
liver disease13 are relevant to the present review. Thus, the guideline recommends that 
lactulose should be the first-choice treatment for an episode of overt HE in patients with 
cirrhosis and for the prevention of recurrent episodes of HE after an index event. The 
findings of this systematic review would support these recommendations. The guideline 
does not recommend routine treatment for minimal HE or primary prophylaxis for 
prevention of the development of HE except in patients known to be at high risk.  This 
review supports a more proactive, evidence-based approach.  Thus, it provides a large 
body of evidence to show that patients with minimal HE benefit from NADs in relation to 
cognitive functioning and probably also quality of life.  It also provides evidence 
supporting the use of NADs for primary prophylaxis in patients with cirrhosis to prevent 
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the development of HE.  These results and their financial implications should be 
considered in the formulation of future versions of the EASL/AASLD guideline. 
Conclusion. This updated 2016 systematic Cochrane review on the efficacy and safety 
of NADs for the treatment and prevention of HE, in patients with cirrhosis found sufficient 
evidence to reach conclusions and make recommendations for clinical practice.  Use of 
NADs had a significant beneficial treatment effect on HE, both minimal and overt, and an 
overall beneficial effect on both liver-related morbidity and all-cause mortality.  In addition 
use of NADs provides effective prophylaxis against the development of HE in both the 
primary and secondary setting.  Notwithstanding the differences in the robustness of the 
sub-group analyses these effects are consistent and support the use of NADs as a first 
line treatment for HE in patients with cirrhosis and for its prevention.  
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Legends to Figures 
Fig. 1. Trial flow chart. 
Fig. 2. Random-effects meta-analysis of randomized controlled trials comparing the 
efficacy of non-absorbable disaccharides versus placebo/no intervention on hepatic 
encephalopathy in patients with cirrhosis, both overall and by type of encephalopathy 
Fig. 3. Random-effects meta-analysis of randomized controlled trials comparing the effect 
of non-absorbable disaccharides versus placebo/no intervention on mortality in patients 
with cirrhosis with either overt or minimal hepatic encephalopathy.  
Fig. 4. Random-effects meta-analysis of prevention randomized controlled trials 
comparing the effects of non-absorbable disaccharides versus placebo/no on mortality in 
patients with cirrhosis, both overall and by type of prevention.  
Page 33 of 61
Hepatology
Hepatology
This article is protected by copyright. All rights reserved.
34 
Table 1. Characteristics of the randomized controlled trials included in the 
systematic review of non-absorbable disaccharides for the treatment and 
prevention of hepatic encephalopathy in patients with cirrhosis 
Agrawal 201221 
Methods Open, parallel-arm, single-center trial. 
Category Secondary prophylaxis. 
Patients 158 patients with cirrhosis and previous overt HE. The trial 
evaluates secondary prevention of HE. 
Interventions Lactulose syrup versus no intervention for 12 months. 
Inclusion period October 2008 to December 2009. 
Country India. 
Brown 197122 
Methods Double-blind, cross-over, single-center trial. 
Category Treatment: overt, chronic. 
Patients 20 patients with advanced cirrhosis stabilized in hospital on a 
low protein diet and then given increasing amounts of protein 
until they developed overt HE. 
Interventions Lactulose syrup versus placebo (sorbitol) for a maximum of 30 
months. 
Inclusion period Not reported. 
Country of origin USA. 
Corazza 198223 
Methods Double-blind, parallel-arm, single-center trial. 
Category Treatment: overt, chronic. 
Patients 32 patients with cirrhosis and chronic HE. 
Interventions Lactulose syrup versus placebo for 10 days. 
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Inclusion period Not reported. 
Country of origin Italy. 
Dhiman 200024 
Methods Open, parallel-arm, single-center trial. 
Category Treatment: minimal. 
Patients 26 patients with cirrhosis and minimal HE.  
Interventions Lactulose syrup versus no intervention for 3 months. 
Inclusion period Not reported. 
Country of origin India. 
Elkington 196925 
Methods Double-blind, cross-over, single-center trial. 
Category Treatment: overt, chronic. 
Patients 7 patients with decompensated cirrhosis and chronic overt 
HE.  
Interventions Lactulose syrup versus placebo (sorbitol) for 15 days. 
Inclusion period Not reported. 
Country of origin USA. 
Germain 197326  
Methods Double-blind, parallel-arm, single-center trial. 
Category Treatment: overt, chronic. 
Patients 18 patients with cirrhosis who developed chronic overt HE 
after portal-systemic shunt surgery. 
Interventions Lactulose syrup versus placebo (saccharose–based) for 15 
days 
Inclusion period Not reported. 
Country of origin France. 
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Grandi 199127  
Methods Open, cross-over, single-center trial. 
Category Treatment: overt, chronic. 
Patients 40 patients with cirrhosis and chronic overt HE. 
Interventions Crystalline lactulose versus lactitol for 60 days. 
Inclusion period Not reported. 
Country of origin Italy. 
Heredia 198728  
Methods Open, parallel-arm, single-center trial 
Category Treatment: overt, acute. 
Patients 40 patients with cirrhosis and an acute episode of overt HE. In 
total, 65% had a previous history of overt HE.  
Interventions Lactulose syrup versus lactitol for 5 days. 
Inclusion period Not reported. 
Country of origin Spain. 
Heredia 198829  
Methods Open, cross-over, single-center trial. 
Category Treatment: overt, chronic. 
Patients 20 patients with cirrhosis and previous portal-systemic shunt 
surgery with chronic/recurrent overt HE. The trial originally 
included 25 patients, but excluded two patients who died and 
three who dropped out.  
Interventions Lactulose syrup versus lactitol for 3 months. 
Inclusion period Not reported. 
Country of origin Spain. 
Horsmans 199730  
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Methods Double-blind, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 14 patients with cirrhosis and minimal HE. 
Interventions Crystalline lactulose versus placebo (lactose) for 15 days. 
Inclusion period Not reported. 
Country of origin Belgium. 
Jain 201331  
Methods Open, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 60 patients with cirrhosis and minimal HE. 
Interventions Lactulose syrup versus no intervention for 3 months. 
Inclusion period October 2011 to February 2012. 
Country of origin India. 
Jankovic 199632  
Methods Open, parallel-arm, single-center trial. 
Category Treatment: overt, acute. 
Patients 16 patients with cirrhosis and an acute episode of overt HE.  
Interventions Lactulose syrup versus lactitol for 5 to 7 days. 
Inclusion period Not reported. 
Country of origin Serbia. 
Li 199933 
Methods Open, parallel-arm, multicenter trial. 
Category Treatment: overt, minimal. 
Patients 86 patients with cirrhosis and minimal HE.  
Interventions Lactulose syrup versus no intervention for 30 days. 
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Inclusion period January 1997 to January 1998. 
Country of origin China. 
McClain 198434 
Methods Double-blind, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 32 patients with cirrhosis and minimal HE.  
Interventions Lactulose syrup versus placebo (sucrose) for 3 months. 
Inclusion period Not reported. 
Country of origin USA. 
Mittal 201135 
Methods Open, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 80 patients with cirrhosis and minimal HE. 
Interventions Lactulose syrup versus no intervention for 3 months. 
Inclusion period October 2007 to October 2009 
Country of origin India. 
Morgan 19875 
Methods Double-blind, parallel-arm, single-center trial. 
Category Treatment: overt, acute. 
Patients 25 patients with cirrhosis randomized during 28 acute 
episodes of overt HE. Only the first randomization period is 
included in the analyses. 
Interventions Lactulose versus lactitol as identically presented liquids for 5 
days. 
Inclusion period July 1984 to December 1985. 
Country of origin United Kingdom. 
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Morgan 19876 
Methods Double-blind, cross-over, single-center trial. 
Category Treatment: overt, chronic. 
Patients 12 patients with cirrhosis and chronic overt HE.  
Interventions Lactulose versus lactitol as identically presented liquids for 3 
months. 
Inclusion period November 1985 to February 1986. 
Country of origin United Kingdom. 
Morgan 19894 
Methods Single-blind, cross-over, single-center trial. 
Category Treatment: overt, minimal. 
Patients 20 patients with cirrhosis, minimal HE, and no history of overt 
HE.  
Interventions Lactulose syrup versus lactitol for 2 months. 
Inclusion period October 1986 to April 1988. 
Country of origin United Kingdom. 
Pai 199536 
Methods Single-blind, parallel-arm, single-center trial. 
Category Treatment: overt, acute. 
Patients 41 patients with cirrhosis and an acute episode of overt HE.  
Interventions Lactulose syrup versus lactitol for 5 days. 
Inclusion period April 1993 to April 1994. 
Country of origin Taiwan. 
Prasad 200737 
Methods Open, parallel arm, single-center trial. 
Category Treatment: overt, minimal. 
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Patients 61 patients with cirrhosis and minimal HE.  
Interventions Lactulose syrup versus no intervention for 3 months. 
Inclusion period January 2004 to March 2005. 
Country of origin India. 
Quero 199738 
Methods Double-blind, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 40 patients with cirrhosis and minimal HE.  
Interventions Crystalline lactulose versus lactose placebo for 6 months. 
Inclusion period October 1992 to September 1994. 
Country of origin Holland. 
Raza 200439 
Methods Open, parallel-arm, single-center trial. 
Category Treatment: overt, acute. 
Patients 31 patients with cirrhosis and an acute episode of overt HE.  
Interventions Lactulose enemata versus tap water enemata administered 
for a mean of 4.5 days. Both groups also received oral 
lactulose. 
Inclusion period Not reported. 
Country of origin Pakistan. 
Riggio 198940 
Methods Single-blind, parallel-arm, single-center trial. 
Category Prophylaxis: Primary/secondary. 
Patients 31 patients with cirrhosis who had undergone portal-systemic 
shunt surgery. The trial evaluates primary prevention for 
53.3% of patients in the lactulose group and 62.5% of patients 
in the lactitol group and secondary prevention for the 
remaining patients. The trial only provided data for the 
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analyses of mortality.  
Interventions Lactulose syrup versus lactitol for 6 months. 
Inclusion period Not described. 
Country of origin Italy. 
Riggio 200541 
Methods Single-blind, parallel-arm, single-center trial. 
Category Prophylaxis: Primary. 
Patients 50 patients with cirrhosis randomized immediately after 
transjugular intrahepatic portosystemic shunt placement. The 
trial evaluates primary prevention for 92% in the lactitol group 
and 76% in the control group and secondary prevention for 
remaining patients. We therefore included the trial as primary 
prevention in our subgroup analyses. 
Interventions Lactitol versus no intervention for 6 months. 
Inclusion period November 1998 to September 2003. 
Country of origin Italy. 
Rodgers 197342 
Methods Double-blind, cross-over, single-center, outpatient trial. 
Category Treatment: overt, chronic. 
Patients 6 patients with cirrhosis and chronic overt HE. Three are 
described in detail.  
Interventions Lactulose syrup versus placebo (sorbitol). 
Inclusion period 1967 to 1970. 
Country of origin USA. 
Sharma 200943 
Methods Open, parallel-arm, single-center, outpatient trial. 
Category Prophylaxis: Secondary. 
Patients 140 patients with cirrhosis who had recovered from an 
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episode of overt HE. The trial evaluates secondary prevention 
of HE.  
Interventions Lactulose syrup versus no intervention for 12 months. 
Inclusion period January 2006 to June 2008. 
Country of origin India. 
Sharma 201144 
Methods Open, parallel-arm, single-center, inpatient trial. 
Category Prophylaxis: Primary. 
Patients 70 patients with cirrhosis who were stable after an acute 
variceal bleed. The trial evaluates primary prevention of HE in 
83% of patients in the lactulose group and 86% of patients in 
the control group and secondary prevention in the remaining 
patients. We included the trial as primary prevention in our 
subgroup analyses. 
Interventions Lactulose syrup versus no intervention for 120 hours. 
Inclusion period December 2008 to January 2010. 
Country of origin India. 
Sharma 201245 
Methods Open, parallel-arm, single-center, outpatient trial. 
Category Prophylaxis: Primary. 
Patients 120 patients with cirrhosis and no history of overt HE. The trial 
evaluates primary prevention of HE.  
Interventions Lactulose syrup versus no intervention for 12 months. 
Inclusion period January 2008 to September 2009. 
Country of origin India. 
Shi 199746 
Methods Double-blind, parallel-arm, single-center, outpatient trial. 
Category Treatment: overt, minimal. 
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Patients 31 patients with cirrhosis and minimal HE. 
Interventions Lactitol versus placebo (glucose) for 2 weeks. 
Inclusion period Not reported. 
Country of origin China. 
Simmons 197047 
Methods Double-blind, parallel-arm, single-center trial. 
Category Treatment: overt, acute. 
Patients 26 patients with cirrhosis; 22 patients with acute HE and 4 
with classified as chronic remittent HE. The trial was included 
in the subgroup analysis of acute HE. 
Interventions Lactulose syrup versus placebo (glucose) for 10 days. 
Inclusion period Not reported. 
Country of origin USA. 
Uribe 198748 
Methods Double-blind, cross-over, single-center trial. 
Category Treatment: overt, acute. 
Patients 37 patients with cirrhosis included during 45 acute episodes of 
overt HE. Data could not be extracted from the first 
randomization period. 
Interventions Rectal lactitol enemata versus rectal placebo enemata 
(lactose or tap water) for 4 days. 
Inclusion period Not reported. 
Country of origin Mexico. 
Uribe 198749 
Methods Double-blind, cross-over, single-center trial. 
Category Treatment: overt, chronic. 
Patients 20 patients with cirrhosis and chronic overt HE. 
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Interventions Lactitol versus placebo (lactose) for 2 weeks. 
Inclusion period Not reported. 
Country of origin Mexico. 
Watanabe 199750 
Methods Open, parallel-arm, multicenter trial. 
Category Treatment: overt, minimal. 
Patients 75 patients with cirrhosis, minimal HE and previous overt HE.  
Interventions Lactulose syrup versus no intervention for 8 weeks. 
Inclusion period Not reported. 
Country of origin Japan. 
Wen 201351 
Methods Open, parallel-arm, single-center trial. 
Category Prophylaxis: Primary. 
Patients 130 patients with cirrhosis experiencing an acute upper 
gastrointestinal hemorrhage and no evidence of overt or 
minimal HE at inclusion. The trial evaluates primary 
prevention of HE. 
Interventions Lactulose syrup versus no intervention for 7 days. 
Inclusion period May 2007 to July 2011. 
Country of origin China. 
Xing 200352 
Methods Open, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 45 patients with cirrhosis and minimal HE.  
Interventions Lactulose syrup versus no intervention for 4 weeks. 
Inclusion period February 2000 to March 2002. 
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Country of origin China. 
Yao 201453 
Methods Open, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 40 patients with cirrhosis and minimal HE. 
Interventions Lactulose syrup versus no intervention for 15 days. 
Inclusion period May 2011 to July 2013. 
Country of origin China. 
Zeng 200354 
Methods Open, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 60 patients with cirrhosis and minimal HE. 
Interventions Lactulose syrup versus no intervention for eight or 24 weeks. 
Inclusion period July 1998 to March 2002. 
Country of origin China. 
Ziada 201355 
Methods Single-blind, parallel-arm, single-center trial. 
Category Treatment: overt, minimal. 
Patients 60 patients with cirrhosis and minimal HE.  
Interventions Lactulose syrup versus no intervention for 4 weeks. 
Inclusion period March 2010 to January 2012. 
Country of origin Egypt. 
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Supplementary Table 1. Database specific search strategies used to identify 
randomized controlled trials on non-absorbable disaccharides for the treatment and 
prevention hepatic encephalopathy in patients with cirrhosis. 
Database Search terms 
The Cochrane 
Hepato-Biliary 
Group Controlled 
Trials Register 
(disaccharid* or lactulos* or lactitol*) AND (encephalopath* OR liver 
disease* OR cirrho*) 
Cochrane Central 
Register of 
Controlled Trials 
(CENTRAL) 
#1 MeSH descriptor: [Disaccharides] explode all trees 
#2 MeSH descriptor: [Lactulose] explode all trees 
#3 disaccharid* or lactulos* or lactitol* 
#4 #1 or #2 or #3 
#5 MeSH descriptor: [Hepatic Encephalopathy] explode all trees 
#6 MeSH descriptor: [Liver Diseases] explode all trees 
#7 MeSH descriptor: [Fibrosis] explode all trees 
#8 encephalopath* or liver disease* or cirrho* 
#9 #5 or #6 or #7 or #8 
#10 #4 and #9 
MEDLINE  
(Ovid SP) 
1. exp Disaccharides/ 
2. exp Lactulose/ 
3. (disaccharid* or lactulos* or lactitol*).mp. [mp=title, abstract, 
original title, name of substance word, subject heading word, 
keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
4. 1 or 2 or 3 
5. exp Hepatic Encephalopathy/ 
6. exp Liver Diseases/ 
7. exp Fibrosis/ 
8. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, 
abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
9. 5 or 6 or 7 or 8 
10. 4 and 9 
11. (random* or blind* or placebo* or meta-analysis).mp. [mp=title, 
abstract, original title, name of substance word, subject heading 
word, keyword heading word, protocol supplementary concept, rare 
disease supplementary concept, unique identifier] 
12. 10 and 11 
EMBASE  
(Ovid SP) 
1. exp disaccharide/ 
2. exp lactulose/ 
3. exp lactitol/ 
4. (disaccharid* or lactulos* or lactitol*).mp. [mp=title, abstract, 
subject headings, heading word, drug trade name, original title, 
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device manufacturer, drug manufacturer, device trade name, 
keyword] 
5. 1 or 2 or 3 or 4 
6. exp hepatic encephalopathy/ 
7. exp liver disease/ 
8. exp fibrosis/ 
9. (encephalopath* or liver disease* or cirrho*).mp. [mp=title, 
abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
10. 6 or 7 or 8 or 9 
11. 5 and 10 
12. (random* or blind* or placebo* or meta-analys*).mp. [mp=title, 
abstract, subject headings, heading word, drug trade name, original 
title, device manufacturer, drug manufacturer, device trade name, 
keyword] 
13. 11 and 12 
Science Citation 
Index Expanded 
5. #4 AND #3 
4. TS=(random* or blind* or placebo* or meta-analysis) 
3. #2 AND #1 
2. TS=(encephalopath* or liver disease* or cirrho*) 
1. TS=(disaccharid* or lactulos* or lactitol*) 
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Supplementary Table 2. Assessment of the Risk of Bias 
Domain Bias risk assessment criteria 
1. Selection bias 
Allocation 
sequence 
generation 
Low: sequence generation achieved using computer random 
number generation or a random number table. Drawing lots, 
tossing a coin, shuffling cards, or throwing dice are adequate if 
performed by an independent person not otherwise involved in 
the trial. 
 Unclear: the method of sequence generation was not specified. 
 High: the sequence generation method was not random. 
Allocation 
concealment 
Low: the participant allocations could not have been foreseen in 
advance of, or during, enrolment. Allocation was controlled by a 
central and independent randomization unit. The allocation 
sequence was unknown to the investigators (for example, if the 
allocation sequence was hidden in sequentially numbered, 
opaque, and sealed envelopes). 
 Uncertain: the method used to conceal the allocation was not 
described so that intervention allocations may have been 
foreseen in advance of, or during, enrolment. 
 High: the allocation sequence was likely to be known to the 
investigators who assigned the participants. 
2. Performance and detection bias 
Blinding  Low: blinding was performed adequately.  The lack of blinding 
was determined as unlikely to affect the assessment of the 
outcome mortality. 
Unclear: there was insufficient information to assess whether 
blinding was likely to induce bias on the results. 
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 High: no blinding or incomplete blinding, and the assessment of 
outcomes were likely to be influenced by lack of blinding. 
3. Attrition bias 
Incomplete 
outcome data 
Low: missing data were unlikely to make treatment effects depart 
from plausible values. The investigators used sufficient methods, 
such as intention-to-treat analyses with multiple imputations or 
carry-forward analyses to handle missing data. 
 Unclear: there was insufficient information to assess whether 
missing data in combination with the method used to handle 
missing data induced bias on the results 
 High: the results were likely to be biased due to missing data. 
4. Reporting bias 
Selective outcome 
reporting 
Low: the trial reported clinically relevant outcomes (mortality, 
hepatic encephalopathy, and serious adverse events). If the 
original trial protocol was available, the outcomes should be those 
called for in that protocol.  
 Unclear: not all pre-defined outcomes were reported fully, or it 
was unclear whether data on these outcomes were recorded or 
not. 
 High: one or more predefined outcomes were not reported. 
5. For–profit bias 
 Low: the trial appears to be free of industry sponsorship or other 
type of for-profit support that may influence the trial design, 
conduct, or results. 
 Unclear: no information on clinical trial support or sponsorship 
was available. 
 High: the trial was sponsored by industry, received support in the 
form of lactulose, lactitol, or placebo, or received any other type 
of support. 
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6. Other bias 
 Low: the trial was free of other biases including: medicinal dosing 
problems or follow up (as defined below). 
 Unclear: the trial may or may not have been free of other 
domains that could put it at risk of bias. 
 High: there were other factors in the trial that could put it at risk of 
bias such as the administration of inappropriate treatments being 
given to the controls (e.g., an inappropriate dose) or follow up 
(e.g., the trial included different follow up schedules for 
participants in the allocation groups). 
Overall bias assessment 
 Low: all domains were low risk of bias using the definitions 
described above. 
 High: one or more of the bias domains were of unclear or high 
risk of bias. 
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Supplementary Table 3. Definitions and assessments of overt hepatic encephalopathy 
in trial publications, and the corresponding definition of hepatic encephalopathy based on 
recommendations in the EASL/AASLD joint guidelines13  
Trial Definition in trial Definition based 
on classification 
in guidelines13 
Assessment of hepatic encephalopathy 
Elkington 
196925* 
Chronic persistent  Persistent • Mental status assessed using 
Parsons-Smith criteria;  
• Arterial blood ammonia 
concentrations; 
• EEG. 
Simmons 
197047 
Acute or chronic 
remittent 
Episodic (85%) or 
recurrent (15%) 
• Mental status assessed on a scale 
similar to the West Haven Criteria; 
• Venous blood ammonia 
concentrations; 
Brown 
197122* 
Chronic persistent  Persistent • Mental status; 
• Blood ammonia concentrations; 
• EEG. 
Germain 
197326 
Chronic persistent  Persistent • Mental status assessed using Parson-
Smith criteria; 
• Psychometric tests; 
• Venous blood ammonia 
concentrations;  
• EEG. 
Rodgers 
197342* 
Chronic persistent  Persistent • Clinical assessment of mental status; 
• Blood ammonia concentrations; 
• EEG. 
Corazza 
198223* 
Chronic persistent  Persistent • Encephalopathy Intensity Score; 
• Plasma ammonia concentrations. 
Heredia 
198728 
Acute  Episodic/recurrent • Conn score; 
• NCT; 
• Blood ammonia concentrations; 
• EEG. 
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Morgan 
1987a5 
Acute  Episodic • PSE Sum and Index. 
Morgan 
1987b6 
Chronic 
persistent. 
Persistent. • PSE Sum and Index. 
Uribe 
1987a48 
Acute  Episodic • PSE Sum and Index. 
Uribe 
1987b49 
Chronic persistent  Persistent • PSE Sum and Index. 
Heredia 
198829* 
Chronic persistent  Persistent • PSE Sum and Index. 
Grandi 
199127 
Chronic  Persistent • PSE Sum and Index modified by 
omitting the EEG. 
Pai 
199536 
Acute  Episodic • PSE Sum and Index. 
Jankovic 
199632* 
Acute  Episodic • Mental status using West Haven 
criteria; 
• NCT-A; 
• EEG. 
Raza 
200439 
Acute  Episodic • Clinical scoring; 
• Modified PSE Sum and Index with 
electroencephalogram omitted and 
Digit Symbol test replacing NCT-A. 
Footnotes 
*Trial not included in the analysis of HE, because data could not be extracted on the 
number of participants with (or without) an overall improvement. 
+ Portal-Systemic Encephalopathy (PSE) sum/index,15 which is calculated utilizing five 
variables, viz: mental status, the presence and severity of asterixis; the NCT-A time, 
blood ammonia concentration; and the EEG mdf.  Each variable is assigned a score of 0 
(no abnormality) to 4 (severe abnormality) and the PSE index calculated as the ratio of 
the points scored and the maximum possible score of 28. 
NCT-A: Number Connection Test-A; EEG: electroencephalogram 
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8 
Supplementary Table 4. Assessment of bias in the randomized controlled trials of 
non-absorbable disaccharides versus placebo/no treatment included in the review.  
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* 
Agrawal 201221 Low High High Low Low Low Low 
Brown 197122 Unclear Low Low High High High High 
Corazza 198223 Unclear Low Low Unclear Low Low High 
Dhiman 200024 Low High High Low Low Low Low 
Elkington 196925 Unclear Low Low Unclear Low High High 
Germain 197326 Low Low Low Low Low High High 
Grandi 199127 Unclear High High Low Low High High 
Heredia 198728 Low High High Low Low High High 
Heredia 198829 Low High High High High High High 
Horsmans 199730 Low Low Low Low Low High High 
Jain 201331 Low High High High High Low High 
Jankovic 199632 Unclear High High High Low Low High 
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Li 199933 Unclear High High Low Low Low High 
McClain 198434 Low Low Low High Low High High 
Mittal 201135 Low High High Low Low Low Low 
Morgan 19875 Low Low Low Low Low High High 
Morgan 19876 Low Low Low Low Low High High 
Morgan 19894 Low High Low Low Low High High 
Pai 199536 Unclear High Low High High Low High 
Prasad 200737 Low High High Low Low Low Low 
Quero 199738 Low Low Low High Low High High 
Raza 200439 Unclear High High Unclear Low High High 
Riggio 198940 Low High Low Low Low High High 
Riggio 200541 Low High Low Low Low Low Low 
Rodgers 197342 Unclear Low Low High High High High 
Sharma 200943 Low High High Low Low Low Low 
Sharma 201144 Low High High Low Low Low Low 
Sharma 201245 Low High High Low Low Low Low 
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Shi 199746 Unclear Low Low Unclear High Low High 
Simmons 197047 Low Low Low Low Low High High 
Uribe 198748 Low Low Low High Low High High 
Uribe 198749 Low Low Low Low Low High High 
Watanabe 199750 Low High High High Low Low High 
Wen 201351 Unclear High Low High Low Low High 
Xing 200352 Unclear High High Low Low Low High 
Yao 201453 Unclear Unclear Unclear Low Low Unclear High 
Zeng 200354 Unclear High High Low Low Low High 
Ziada 201355 Unclear High Low High Low Low High 
*Individual domains were assessed as low risk, unclear risk (insufficient information 
provided) or high risk of bias.  The overall bias assessment included all domains for non-
mortality outcomes and was classified as low risk of bias if all domains were assessed as 
such.  The overall bias assessment for mortality outcomes did not include performance or 
detection bias.  None of the included trials were classified as low risk of bias in the 
assessment of non-mortality outcomes.  *Mortality was defined as an outcome unlikely to 
be influenced by lack of blinding.  Accordingly, blinding was not included in the overall 
assessment of bias for this outcome.  
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Supplementary Table 5. Serious adverse events* in 24 randomized controlled trials 
evaluating non-absorbable disaccharides (NADs) versus placebo/no intervention for the 
treatment or prevention of hepatic encephalopathy in people with cirrhosis.  
Treatment trials 
(n=18)  
NADs 
 
(n=433) 
Placebo/no 
intervention 
(n=386) 
 n (%) 
Liver failure 1 (0.2) 2 (0.5) 
Variceal bleeding 2 (0.4) 4 (1) 
Mortality associated with severe liver disease 17 (4) 33 (9) 
Total number of serious adverse events  20 (5) 39 (11) 
   
Prevention trials 
(n = 6) 
NAD 
 
(n=335) 
Placebo/no 
intervention 
(n=333) 
 n (%) 
Liver failure 1 (0.3) 5 (2) 
Hepatorenal syndrome 6 (2) 7 (2) 
Infections (pneumonia and urinary tract) 5 (1) 7 (2) 
Spontaneous bacterial peritonitis 10 (3) 16 (5) 
Variceal bleeding 5 (1) 14 (4) 
Mortality associated with severe liver disease 17 (5) 33 (10) 
Total number of serious adverse events 51 (15) 110 (33) 
*Defined as any untoward medical occurrence that lead to death, were life threatening or 
required hospitalization or prolongation of hospitalization. 
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